UK's National Institute for Health and Care Excellence has endorsed Novartis’ CAR-T therapy, Kymriah, in adult lymphoma patients, after negotiating a deeper discount.
Kymriah, the only CAR-T cell therapy available for NHS patients for two distinct blood cancers, will now be available to adults who did not respond to two or more previous treatments with DLBCL, with funding from the Cancer Drugs Fund. NICE originally said the drug was not cost-effective, but further negotiations between NHS and Novartis led to an agreement to offer the therapy at a lower price.
Back in August, Novartis announced that the European Commission approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.
Read the press release
